Close

LEO Pharma invests in mobile application company

News
Typography

LEO Pharma A/S, a global healthcare company dedicated to helping people achieve healthy skin, invests in privately owned SkinVision B. V., a derma focused mobile app company based in Amsterdam, Netherlands.

Ballerup, Denmark, 20 August 2015 – This agreement is one in a series of recent deals for LEO Pharma and illustrates the company’s ambition to provide easy access to better care solutions for people with skin diseases.

“The Internet is dramatically changing how consumers manage their health and this creates new opportunities for us to deliver innovative, value-added services and LEO Pharma wants to be at the forefront of that trend,” said Kim Kjoeller, Senior Vice President of Global Development at LEO Pharma. “I’m very pleased to announce our investment in SkinVision as this deal will provide access to unique digital learnings that will ultimately help us address the unmet needs of individual patients in an ever changing and increasingly digital healthcare environment.”

SkinVision is known for its early self-detection skin assessment app for smartphones. The current focus area of the app is melanoma – but is likely to expand into other skin disease areas.

“We are delighted to reach this agreement with LEO Pharma, because it will enable us to expand into new areas and it validates our approach,” said Dick Uyttewaal, CEO of SkinVision B.V.  “LEO Pharma has a great reputation and range of products in the treatment of skin conditions, so there is clear synergy between the two companies.  We want to be the leading provider of digital solutions for skin conditions and together with LEO Pharma we believe we can provide consumers with even more personalised, informative healthcare services.”

The overall agreement covers both an equity investment as well as a Letter of Intent outlining possible future collaboration projects.

LEO Pharma has invested in SkinVision along with majority shareholder Personal Health Solutions (PHS) Capital, a Dutch investment firm focusing on science based, technology enabled solutions that provide an enhanced quality of life and reduces the risk of chronic illness.

Subscribe to our Newsletter
captcha